Superworth

Utah Medical Products PE ratio UTMD

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Nov 2, 2026
21.5×
10-year median
20.9×
Against its 10-year history
57th
percentile: 0 is its lowest day, 100 its highest
10-year range
13.2× to 47.4×
Peer median
17.4×

Utah Medical Products' PE ratio is 21.5× as of Nov 2, 2026: a share price of $70.55 against $3.28 of earnings per share over the last twelve months.

That is above its ten-year median of 20.9×, close to the middle of its last ten years.

Over that time it ranged from 13.2× in Apr 2025 to 47.4× in Jun 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 17.4×.

PE ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far21.5×16.0×22.7×
202516.0×13.2×17.0×
202414.5×14.3×18.1×
202318.2×16.3×22.6×
202222.9×18.9×24.5×
202125.9×24.5×31.2×
202026.6×19.6×29.5×
201929.4×16.3×29.5×
201824.3×21.8×47.4×
201722.1×18.3×22.5×
201621.8×17.4×21.8×
201519.0×17.1×20.8×
201419.1×15.6×21.1×
201321.5×14.8×21.5×
201213.5×13.1×14.7×

Against its peers

Companies in Medical - Instruments & Supplies nearest Utah Medical Products' size, closest first, today.

CompanyPE ratio
UTMDUtah Medical Products21.5×
PDEXPro DEX15.9×
INFUInfuSystem33.8×
EMBCEmbecta4.2×
TCMDTactile Systems Technology21.2×
KEQUKewaunee Scientific12.1×
MOVMovado17.7×
APTAlpha Pro Tech13.5×
IRMDIradimed42.5×
IARTIntegra Lifesciences80.1×
BVSBioventus17.1×
Peer median17.4×

Where Utah Medical Products ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Utah Medical Products

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.